GlassScriptPhysician profile
Mark Durant Davis
NPI 1679580435
$1,038,650.45
in general payments reported to CMS, 2019-2025
68 companies · $227K in 2025
The $227K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139K · 2022: $303K · 2023: $151K · 2024: $219K · 2025: $227K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $362K · Travel and Lodging: $135K · Consulting Fee: $37K · Food and Beverage: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Honoraria: $7,098 · Education: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $362,437.60 |
| Travel and Lodging | $135,309.85 |
| Consulting Fee | $36,756.97 |
| Food and Beverage | $28,099.45 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,474.97 |
| Honoraria | $7,097.50 |
| Education | $597.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $274,788.67 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Glaxosmithkline, LLC. | $200,966.76 | 2021-2025 | Ojjaara, Blenrep |
| Incyte Corporation | $104,327.46 | 2021-2025 | Monjuvi, Jakafi, Monjuvi |
| Sobi, INC | $83,012.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70,033.86 | 2021-2025 | Ninlaro, Iclusig, Fruzaqla |
| Cti Biopharma Corp. | $57,768.57 | 2022-2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $42,128.62 | 2021-2025 | Reblozyl, Opdivo, Krazati |
| Jazz Pharmaceuticals INC. | $41,324.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $29,578.52 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $27,975.03 | 2021-2025 | Calquence, Lynparza, Imfinzi |
| Rigel Pharmaceuticals, INC. | $22,910.74 | 2021-2023 | Rezlidhia, Tavalisse |
| Geron Corporation | $19,288.35 | 2025 | Rytelo |
| Celgene Corporation | $18,090.85 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Mirati Therapeutics, INC. | $8,684.72 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $5,675.46 | 2021-2025 | Xpovio |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $3,749.02 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $3,684.35 | 2025 | |
| Genmab U.S., INC. | $3,595.21 | 2023-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $3,299.54 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Ipsen Biopharmaceuticals, INC | $2,978.69 | 2021-2024 | Tazverik, Onivyde |
| Amgen INC. | $2,444.47 | 2021-2023 | Kyprolis, Lumakras, Blincyto |
| Janssen Pharmaceuticals, INC | $1,280.00 | 2025 | |
| Beigene USA, INC. | $1,147.61 | 2022-2023 | Brukinsa |
| Pharmaessentia USA Corporation | $1,096.66 | 2022-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $768.26 | 2021-2025 | Clonoseq |
| Secura Bio, INC. | $741.27 | 2023-2025 | Copiktra |
| Janssen Scientific Affairs, LLC | $698.75 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $617.64 | 2021-2025 | |
| Lilly USA, LLC | $561.56 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $557.75 | 2021-2025 | |
| Seagen INC. | $480.53 | 2021-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $454.79 | 2021-2025 | |
| Gilead Sciences, INC. | $431.02 | 2022-2025 | Trodelvy |
| Abbvie INC. | $409.71 | 2023-2025 | |
| Astellas Pharma US INC | $381.32 | 2021-2025 | Xtandi |
| Tg Therapeutics, INC. | $285.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $263.93 | 2022-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $181.93 | 2021-2025 | Monoferric, Cosela |
| Genzyme Corporation | $174.39 | 2021-2025 | |
| Array Biopharma INC | $162.58 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Tempus Ai, INC | $152.15 | 2024 | |
| Kite Pharma, INC. | $141.22 | 2021-2025 | Yescarta |
| Genentech USA, INC. | $135.72 | 2022-2024 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Stemline Therapeutics INC. | $131.02 | 2023-2025 | Orserdu |
| Morphosys, US INC. | $125.91 | 2021-2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $122.20 | 2023-2025 | Qinlock, Tgct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.84 | 2022-2024 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $97.32 | 2023-2025 | |
| Emd Serono, INC. | $89.12 | 2023-2024 | Bavencio, Tepmetko |
| Servier Pharmaceuticals LLC | $86.43 | 2024-2025 | |
| Kyowa Kirin, INC. | $70.52 | 2023-2025 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $48.17 | 2021-2023 | Imbruvica |
| Beone Medicines USA, INC. | $45.33 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $30.66 | 2021-2023 | Ayvakit |
| Puma Biotechnology, INC. | $25.81 | 2025 | |
| Syndax Pharmaceuticals, INC. | $25.29 | 2025 | |
| Exelixis INC. | $23.44 | 2022 | |
| Shield Therapeutics INC | $21.97 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.32 | 2023 | Ultomiris |
| Adc Therapeutics America, INC. | $18.16 | 2024 | |
| Caris Mpi, INC. | $17.52 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $17.52 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $17.44 | 2022 | |
| Acceleron Pharma, INC. | $17.32 | 2021 | |
| Pharmaand Gmbh | $17.30 | 2025 | Rubraca |
| Tolmar, INC. | $17.30 | 2025 | Rubraca, Eligard |
| Spectrum Pharmaceuticals INC. | $17.21 | 2025 | Rolvedon |
| G1 Therapeutics, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.